References:
[1] Chung, CS, Morton, NE. Discrimination of genetic entities in muscular dystrophy. Am. J. Hum. Genet. 11: 339-359, 1959. [2] Fanin, M et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum. Mutat. 24: 52-62, 2004. [3] Jensen LJ, et al. STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009 Jan;37 [4] Kinbara K, Sorimachi H, Ishiura S, Suzuki K. Muscle-specific calpain, p94, interacts with the extreme C-terminal region of connectin, a unique region flanked by two immunoglobulin C2 motifs. Arch Biochem Biophys. 1997 Jun 1;342(1):99-107 [5] Laure, L. et al. A new pathway encompassing calpain 3 and its newly identified substrate cardiac ankyrin repeat protein is involved in the regulation of the nuclear factor-κB pathway in skeletal muscle. FEBS J. 277, 4322–4337 (2010). |
[6] Mourkioti, F. & Rosenthal, N. NF-κB signaling in skeletal muscle: prospects for intervention in muscle diseases. Journal of Molecular Medicine 86, 747–759 (2008). [7] Miller MK, Bang ML, et al. (2003). The Muscle Ankyrin Repeat Domain Proteins: CARP, anrkd2/Arpp, and DARP as a family of Titin Filament-based Stress Response Molecules. J. Mol. Biol. 333, 951-964. [8] Richard, I. et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J. Cell Biol. 151, 1583–1590 (2000). |